Dyslipidaemia in adults with type 1 diabetes-when to treat?

Nick S. R. Lan, P. Gerry Fegan, Bu B. Yeap, Damon A. Bell, Gerald F. Watts

Research output: Contribution to journalEditorial

1 Citation (Scopus)

Abstract

Dyslipidaemia is an important modifiable risk factor contributing to the increased risk of atherosclerotic cardiovascular disease in diabetes. However, determining when to initiate statin therapy in young adults with type 1 diabetes mellitus (T1DM) can often be challenging. This is due to a relative paucity of data in this area to guide management and for developing T1DM-specific risk engines. Current recommendations from international guidelines offer differing approaches to cardiovascular risk stratification and management of dyslipidaemia in T1DM. We present a clinical vignette and comment on the use of nontraditional methods of cardiovascular risk stratification. The strategy for managing dyslipidaemia in young T1DM should be individualized, and recommendations from guidelines should serve to inform clinical judgement.

Original languageEnglish
Article number3090
Number of pages5
JournalDiabetes/Metabolism Research and Reviews
Volume35
Issue number1
DOIs
Publication statusPublished - Jan 2019

Cite this

@article{77ef076328fa4ca8a6eb4e96a8df0262,
title = "Dyslipidaemia in adults with type 1 diabetes-when to treat?",
abstract = "Dyslipidaemia is an important modifiable risk factor contributing to the increased risk of atherosclerotic cardiovascular disease in diabetes. However, determining when to initiate statin therapy in young adults with type 1 diabetes mellitus (T1DM) can often be challenging. This is due to a relative paucity of data in this area to guide management and for developing T1DM-specific risk engines. Current recommendations from international guidelines offer differing approaches to cardiovascular risk stratification and management of dyslipidaemia in T1DM. We present a clinical vignette and comment on the use of nontraditional methods of cardiovascular risk stratification. The strategy for managing dyslipidaemia in young T1DM should be individualized, and recommendations from guidelines should serve to inform clinical judgement.",
keywords = "diabetes mellitus, type 1, dyslipidaemias, cardiovascular diseases, statins, risk factors, CARDIOVASCULAR-DISEASE, ASSOCIATION, MANAGEMENT, GUIDELINES, PREVENTION",
author = "Lan, {Nick S. R.} and Fegan, {P. Gerry} and Yeap, {Bu B.} and Bell, {Damon A.} and Watts, {Gerald F.}",
year = "2019",
month = "1",
doi = "10.1002/dmrr.3090",
language = "English",
volume = "35",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley & Sons",
number = "1",

}

Dyslipidaemia in adults with type 1 diabetes-when to treat? / Lan, Nick S. R.; Fegan, P. Gerry; Yeap, Bu B.; Bell, Damon A.; Watts, Gerald F.

In: Diabetes/Metabolism Research and Reviews, Vol. 35, No. 1, 3090, 01.2019.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Dyslipidaemia in adults with type 1 diabetes-when to treat?

AU - Lan, Nick S. R.

AU - Fegan, P. Gerry

AU - Yeap, Bu B.

AU - Bell, Damon A.

AU - Watts, Gerald F.

PY - 2019/1

Y1 - 2019/1

N2 - Dyslipidaemia is an important modifiable risk factor contributing to the increased risk of atherosclerotic cardiovascular disease in diabetes. However, determining when to initiate statin therapy in young adults with type 1 diabetes mellitus (T1DM) can often be challenging. This is due to a relative paucity of data in this area to guide management and for developing T1DM-specific risk engines. Current recommendations from international guidelines offer differing approaches to cardiovascular risk stratification and management of dyslipidaemia in T1DM. We present a clinical vignette and comment on the use of nontraditional methods of cardiovascular risk stratification. The strategy for managing dyslipidaemia in young T1DM should be individualized, and recommendations from guidelines should serve to inform clinical judgement.

AB - Dyslipidaemia is an important modifiable risk factor contributing to the increased risk of atherosclerotic cardiovascular disease in diabetes. However, determining when to initiate statin therapy in young adults with type 1 diabetes mellitus (T1DM) can often be challenging. This is due to a relative paucity of data in this area to guide management and for developing T1DM-specific risk engines. Current recommendations from international guidelines offer differing approaches to cardiovascular risk stratification and management of dyslipidaemia in T1DM. We present a clinical vignette and comment on the use of nontraditional methods of cardiovascular risk stratification. The strategy for managing dyslipidaemia in young T1DM should be individualized, and recommendations from guidelines should serve to inform clinical judgement.

KW - diabetes mellitus, type 1

KW - dyslipidaemias

KW - cardiovascular diseases

KW - statins

KW - risk factors

KW - CARDIOVASCULAR-DISEASE

KW - ASSOCIATION

KW - MANAGEMENT

KW - GUIDELINES

KW - PREVENTION

U2 - 10.1002/dmrr.3090

DO - 10.1002/dmrr.3090

M3 - Editorial

VL - 35

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 1

M1 - 3090

ER -